Iovance Biotherapeutics Inc. (NASDAQ:IOVA) shares traded -0.96% lower at $6.22 on Wall Street last session.
In accordance with the data, 15 analysts cover Iovance Biotherapeutics Inc. (NASDAQ:IOVA). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $40.00 and a low of $11.00, we find $25.00. Given the previous closing price of $6.28, this indicates a potential upside of 298.09 percent. IOVA stock price is now -31.96% away from the 50-day moving average and -49.09% away from the 200-day moving average. The market capitalization of the company currently stands at $1.05B.
It has been rated a hold by 3 analysts and a buy by 10. Brokers who have rated the stock have averaged $24.85 as their price target over the next twelve months.
, while ‘Stifel’ rates the stock as ‘Buy’.
In other news, Vogt Frederick G, Interim CEO & General Counsel bought 1,000 shares of the company’s stock on Jun 01. The stock was bought for $6,440 at an average price of $6.44. Upon completion of the transaction, the Interim CEO & General Counsel now directly owns 1,000 shares in the company, valued at $6220.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 01, Director Rothbaum Wayne P. bought 500,000 shares of the business’s stock. A total of $3,215,500 was incurred on buying the stock at an average price of $6.43. This leaves the insider owning 8,067,333 shares of the company worth $50.18 million. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IOVA stock. A new stake in Iovance Biotherapeutics Inc. shares was purchased by RENAISSANCE TECHNOLOGIES LLC during the first quarter worth $5,029,000. BANK OF MONTREAL /CAN/ invested $4,215,000 in shares of IOVA during the first quarter. In the first quarter, SQUAREPOINT OPS LLC acquired a new stake in Iovance Biotherapeutics Inc. valued at approximately $2,291,000. SCHONFELD STRATEGIC ADVISORS LLC acquired a new stake in IOVA for approximately $1,077,000. OCCUDO QUANTITATIVE STRATEGIES LP purchased a new stake in IOVA valued at around $1,063,000 in the second quarter.
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) opened at $6.28 on Wednesday. During the past 12 months, Iovance Biotherapeutics Inc. has had a low of $5.42 and a high of $20.60. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.70, and a quick ratio of 4.70. The fifty day moving average price for IOVA is $9.04 and a two-hundred day moving average price translates $12.17 for the stock.
The latest earnings results from Iovance Biotherapeutics Inc. (NASDAQ: IOVA) was released for Jun, 2022.
Iovance Biotherapeutics Inc.(IOVA) Company Profile
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l’Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.